PHAXIAM Therapeutics S.A. (PHXM.PA)

EUR 0.68

(-3.66%)

Operating Expenses Summary of PHAXIAM Therapeutics S.A.

  • PHAXIAM Therapeutics S.A.'s latest annual operating expenses in 2023 was 24.98 Million EUR , down -14.36% from previous year.
  • PHAXIAM Therapeutics S.A.'s latest quarterly operating expenses in 2024 Q2 was 5.87 Million EUR , down 0.0% from previous quarter.
  • PHAXIAM Therapeutics S.A. reported a annual operating expenses of 29.17 Million EUR in annual operating expenses 2022, down -47.26% from previous year.
  • PHAXIAM Therapeutics S.A. reported a annual operating expenses of 55.31 Million EUR in annual operating expenses 2021, down -18.12% from previous year.
  • PHAXIAM Therapeutics S.A. reported a quarterly operating expenses of 5.87 Million EUR for 2024 Q1, down -7.68% from previous quarter.
  • PHAXIAM Therapeutics S.A. reported a quarterly operating expenses of 5.75 Million EUR for 2023 Q3, down -53.63% from previous quarter.

Annual Operating Expenses Chart of PHAXIAM Therapeutics S.A. (2023 - 2016)

Historical Annual Operating Expenses of PHAXIAM Therapeutics S.A. (2023 - 2016)

Year Operating Expenses Operating Expenses Growth
2023 24.98 Million EUR -14.36%
2022 29.17 Million EUR -47.26%
2021 55.31 Million EUR -18.12%
2020 67.55 Million EUR 3.71%
2019 65.14 Million EUR 37.8%
2018 47.27 Million EUR 40.17%
2017 33.72 Million EUR 30.79%
2016 25.78 Million EUR 0.0%

Peer Operating Expenses Comparison of PHAXIAM Therapeutics S.A.

Name Operating Expenses Operating Expenses Difference
Nicox S.A. -11.5 Million EUR 317.213%
European Medical Solutions 13.64 Million EUR -83.088%
FERMENTALG 12.34 Million EUR -102.414%
argenx SE 1.34 Billion EUR 98.139%
BioSenic S.A. 7.58 Million EUR -229.5%
Celyad Oncology SA 8.49 Million EUR -194.299%
Hyloris Pharmaceuticals SA 17.98 Million EUR -38.911%
Onward Medical N.V. 20.64 Million EUR -21.027%
Oxurion NV 12.21 Million EUR -104.569%
Financière de Tubize SA 114.38 Thousand EUR -21743.009%
UCB SA 2.94 Billion EUR 99.15%